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Background: Identification of serum proteins that track with disease course in sarcoidosis may have clinical and
pathologic importance. We previously identified up-regulated transcripts for interferon-inducible chemokines CXCL9,
and CXCL10, in blood of sarcoidosis patients compared to controls. The objective of this study was to determine
whether proteins encoded by these transcripts were elevated in serum and identified patients with remitting vs.
chronic progressive sarcoidosis longitudinally.
Methods: Serum levels of CXCL9, CXCL10, and proteins associated with inflammation and/or disease activity (sIL2R,
ACE, ESR and CRP) were measured in a prospective cohort of sarcoidosis subjects and controls. Comparisons were
made between groups and clinical course using pulmonary function measures and a severity score developed by
Wasfi et al.
Results: In a cross-sectional analysis of 36 non-immunosuppressed sarcoidosis subjects, serum CXCL9, CXCL10, and
sIL2R were significantly elevated compared to 46 controls (p < 0.0001). CXCL9 and CXCL10 were strongly inter-
correlated (p = 0.0009). CXCL10 and CXCL9 were inversely correlated with FVC% predicted and DLCO% predicted,
respectively. CXCL10 and CXCL9 significantly correlated with sarcoidosis severity score. sIL2R, ESR, CRP, and ACE
serum levels did not correlate with pulmonary function measures or severity score. In the longitudinal analysis of
26 subjects, changes in serum CXCL10 level over time corresponded with progression versus remission of disease.
Conclusions: Interferon-γ–inducible chemokines, CXCL9 and CXCL10, are elevated in sarcoidosis and inter-
correlated with each other. Chemokine levels correlated with measures of disease severity. Serial measurements of
CXCL10 corresponded to clinical course.
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Sarcoidosis is a systemic inflammatory disease character-
ized by the presence of noncaseating granulomas that
predominantly affect the lungs. The natural course of
sarcoidosis is heterogeneous; the majority of patients
have a self-limiting course, but one-third of patients de-
velop progressive disease [1,2]. Our prior study revealed
a robust peripheral blood gene expression signature in
sarcoidosis with an over-representation of genes related
to interferon (IFN) Type I and II signaling pathways [3].* Correspondence: laura.koth@ucsf.edu
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reproduction in any medium, provided the orNotably, many of these IFN pathway-related genes were
also upregulated in lung tissue from sarcoidosis subjects
compared to controls, such as downstream signaling
molecules (e.g. IRF1), which correlated with the severity
of lung disease, suggesting a concordance of gene regu-
lation in both blood and lung tissue compartments [3].
In addition to upregulation of genes downstream of IFN
signaling pathways, we also found concordance in the
blood and lung of increased transcript levels for several
chemokine genes that are directly induced by IFN-γ [3].
These genes include CXCL9 (aka, Monokine induced by
IFN-γ or MIG) and CXCL10 (aka, IFN-γ-inducible pro-
tein, 10 kDa or IP-10). Prior experimental studies have
shown that a major source of these chemokines are mono-This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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signal through the receptor, CXCR3, which is an inflam-
matory receptor found on CD4+ Th-1 and CD8+ cyto-
toxic T cells [6]. Additional evidence suggests that CXCR3
and its ligands promote recruitment of T cells into in-
flamed peripheral tissue in human autoimmune diseases
[7–9]. In sarcoidosis, several studies have identified ele-
vations of these chemokines in bronchoalveolar lavage
fluid (BALF) [10–13], suggesting they may contribute
to lung inflammation. Therefore, since transcripts for
these chemokines are upregulated in lung tissue ([14],
GSE16538), and the proteins themselves were shown to
be elevated in BALF, we hypothesized that blood levels
of these chemokines could reflect disease severity and
clinical course in sarcoidosis. We tested this hypothesis
in a well-characterized prospective cohort of sarcoid-
osis and control subjects. Understanding how longitu-
dinal assessment of these circulating chemokines relate
to disease course may lead to new non-invasive ways to
predict which patients will have persistent and/or pro-
gressive disease and to determine which patients may
be suitable for therapies which target interferons.
Methods
Study population and clinical data
We collected blood samples and clinical data prospect-
ively from a longitudinal cohort of sarcoidosis subjects
and healthy controls at University of California San
Francisco (UCSF) recruited from the community at
large. Exclusion criteria included a medical history of
chronic infection, tuberculosis, autoimmune diseases,
cancer, diabetes or any condition associated with im-
mune dysregulation. All sarcoidosis subjects met diag-
nostic criteria based upon established ATS guidelines
[15]. Duration of disease was defined as time since date
of biopsy confirmation of sarcoidosis. All sarcoidosis
subjects had spirometry values within 6 months of blood
draws [16]. Spirometry (nSpire HDpft 1000, Longmont,
CO, USA) was performed at each subsequent follow-up
visit using ATS guidelines [17]. The study was approved
by the Committee on Human Research at UCSF (IRB
10–03759).
For the cross-sectional analysis, only subjects who had
at least one baseline serum sample and were not on im-
munosuppressive therapy within 3 months of the blood
draw were included to avoid any unknown and potential
effects of immunosuppression on serum protein levels.
(See Additional file 1 for patient selection flowchart).
In contrast, the longitudinal analysis included sarcoid-
osis patients with at least two serum samples collected at
6 to 12 month intervals, regardless of whether or not
they had received immunosuppressive therapy within
3 months of the blood draw (see Additional file 1). Based
on prior studies [18–21], subjects in the longitudinalanalysis were classified into one of two groups: chronic
versus remitting. Chronic sarcoidosis subjects were de-
fined as individuals who required systemic immunosup-
pression for recurrent or ongoing disease activity 2 years
after their initial diagnosis. Remitting sarcoidosis sub-
jects were defined as patients who either A) did not re-
quire systemic immunosuppression beyond 2 years after
diagnosis or B) never required immunosuppression ever
since diagnosis.
Levels of routine inflammatory markers were obtained
for all subjects. Serum C-reactive protein (CRP) level
and erythrocyte sedimentation rate (ESR) testing was
performed by the UCSF CLIA-approved clinical labora-
tory. Angiotensin converting enzyme (ACE) level was
measured by Quest Diagnostics Nichols Institute (San
Juan Capistrano, CA, USA). All sarcoidosis subjects were
radiographically classified using Scadding stage and
assigned a clinical sarcoidosis severity score developed
and published by Wasfi et al. [22]. The Wasfi score is a
model built using backward regression multivariate ana-
lysis to identify variables reflective of sarcoidosis severity,
relying on clinical assessment scores by a panel of inde-
pendent sarcoidosis experts at National Jewish Medical
and Research Center as the “gold standard” for deter-
mining disease severity. We recognize that a major
limitation to this model is that there is no universally-
recognized “gold standard” in evaluating sarcoidosis se-
verity (a motivating factor in the design of our study)
but this severity scoring model was selected for the
purposes of our study because the model had been vali-
dated by a separate international panel of sarcoidosis
experts, incorporates extrapulmonary sites of involve-
ment, and utilizes clinical variables that are easily
accessible to clinicians at a single patient visit. The se-
verity score is calculated as follows:
Severity Score = 11.46 + 3.9(Cardiac) + 2.56(Neuro) +
1.56(Immunosuppression within 30 days) – 0.051(FVC%
predicted) +1.75(African American) – 0.054(FEV1/FVC
ratio)
where Cardiac = 1 if there is cardiac involvement, 0 if not;
Neuro = 1 if there is neurologic involvement, 0 if not; Im-
munosuppression = 1 if receiving noncorticosteroid im-
munosuppression therapy, 0 if not; African American = 1 if
the subject was African American, 0 if not; FVC= forced
vital capacity; FEV1 = forced expiratory volume in 1 second.Sample processing
Blood samples were collected in 10-ml Vacutainer red/
gray tubes (BD, Franklin Lakes, NJ, USA). Samples were
processed for serum after incubation at room temperature
for 30 minutes and then centrifugation at 2400 rpm for
12 minutes. Samples were aliquoted and stored at −80°C
until thawed for Luminex assays.
Table 1 Cross-sectional cohort characteristics
Control Sarcoidosis P-Value
N = 46 (%) N = 36 (%)
Female 28 (61%) 23 (64%) 0.82
Age (y)* 42.15 ± 12.96 52.06 ± 11.57 <0.01
Race
African-American 5 (11%) 2 (5%) 0.46
White 33 (72%) 33 (92%) 0.02
Other 8 (17%) 1 (3%) 0.50
Ethnicity
Hispanic 6 (13%) 2 (5%) 0.46
Smoking Status
Ever 11 (24%) 14 (39%) 0.16
Current 4 (8.7%) 1 (3%) 0.38
Cardiac/ocular/CNS n/a 1/9/7
Pulmonary Function Range
FEV1 (%)* 93.9 ± 17.5 47-133
FVC (%)* 100.0 ± 13.8 63-129
FEV1/FVC (%)* 72.9 ± 8.4 56.2-94.8
TLC (%)* N = 25 99.9 ± 15.0 62-124
DLCO (%)* N = 27 87.77 ± 15.7 45-120
Immunosuppression None No immunosuppression at time of
or within 3 months of blood draw
*Data are presented as mean ± standard deviation.
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Multiplex bead-based assay kits for CXCL9, CXCL10,
and sIL2R were purchased from Luminex Corporation
(Austin, TX, USA). The multiplex assay also measured
IL6, IL2, IL15, TNF-α, and CCL3; however, the concen-
trations of these analytes were below the lower limit of
quantitation and thus excluded from further studies.
The lowest detectable levels for sIL2R, CXCL10, and
CXCL9 were 29.4 pg/ml, 1.6 pg/ml, and 12.3 pg/ml, re-
spectively. Nine standard control samples were analyzed
to ensure validity of results. All samples were analyzed
in duplicate, and the averaged values were used for each
sample. Measurements with a coefficient of variation less
than 0.2 between duplicate samples were included for
data analysis.
Statistical analysis
Fisher’s exact test was used to compare nominal clinical
characteristics between sarcoidosis and control subjects.
Distribution of sIL2R, CXCL9, and CXCL10 levels were
assessed for normality and log10 transformation was ap-
plied for non-parametric data. In some instances, the
distribution of data remained non-parametric even after
transformation. Therefore, unpaired two-tailed t-test or
the Wilcoxon rank sum statistic, as appropriate, was
used to compare differences between groups. A non-
parametric test for trend was performed in Stata version
12 (StataCorp, College Station, TX, USA) in sensitivity
analyses to assess the effects of immunosuppression [23].
Pearson’s correlation coefficient or Spearman’s rank cor-
relation coefficient was used, as appropriate, to evaluate
the relationships between CXCL9 and CXCL10 and pul-
monary function measurements and severity score in sar-
coidosis subjects. Cross-sectional analyses were performed
in JMP version 10 (SAS, Cary, NC, USA). P < 0.05 was
considered statistically significant.
Results
Cross-sectional study patient characteristics and baseline
blood measurements
The clinical characteristics of the cross-sectional study
population are summarized in Table 1 and Additional
file 2. Despite the mean age of the sarcoidosis group be-
ing older than the control group, there were no statisti-
cally significant relationships between CXCL9, CXCL10,
and sIL2R levels and age at blood draw or duration of
disease (p > 0.5). Gender, ethnicity and smoking status
were similar between the two groups. All subjects in
this cross-sectional analysis had pulmonary sarcoid-
osis. In addition, 17 also had extrapulmonary involve-
ment (1 subject had cardiac sarcoidosis, 9 subjects had
ocular sarcoidosis, 7 subjects had central nervous system
sarcoidosis). Sarcoidosis subjects were lymphopenic com-
pared to control subjects (Table 2). The concentrations ofACE, CRP, ESR, CXL9, CXCL10, and sIL2R were all sig-
nificantly elevated in sarcoidosis subjects when compared
to control subjects (Table 2).
Sarcoidosis and control serum protein comparisons
We found statistically significant increases in CXCL9,
CXCL10, and sIL2R in sarcoidosis subjects compared to
control subjects (Figure 1). We also found significant inter-
correlation between the two chemokines within each sub-
ject (Figure 2). CXCL9 was weakly inter-correlated with
sIL2R (Spearman’s ρ = 0.3764, p = 0.04), while CXCL10
was not (Spearman’s ρ = 0.0931, p = 0.59).
Correlations with disease severity
There were significant inverse correlations between
CXCL10 and FVC% predicted (Figure 3A) and CXCL9
and DLCO (diffusing capacity) % predicted (Figure 3B).
There was a trend for CXCL10 and DLCO% predicted
(Pearson’s R = −0.37, p = 0.056). As an alternative
method to examine how these chemokines related to
disease severity, we used a severity score developed by
Wafsi et al. which incorporates lung function measures,
presence of cardiac and/or neurologic disease, and im-
munosuppression use [22]. Using this equation, both
CXCL10 and CXCL9 were significantly correlated with
Table 2 Blood and Serum Measurements*
Group Lymphocytes (x109/L) ACE (U/L) CRP (mg/L) ESR (mm/h) CXCL9 (pg/ml) CXCL10 (pg/ml) sIL-2R (pg/ml)
Control
1.68 36.5 1.6 5 29.4 15.53 12.38
(1.1-3.1) (0–101) (0–24.5) (0–30) (29.4-73.3) (6.6-25.0) (12.3-58.6)
N = 46 N = 46 N = 46 N = 44 N = 34 N = 46 N = 46
Sarcoidosis
1.26† 50‡ 2.8¥ 9¥ 56.73† 28.72† 40.84†
(0.6-2.1) (0–147) (0.9-18.3) (0–55) (29.4-165.9) (13.3-80.1) (12.3-158.6)
N = 35 N = 35 N = 35 N = 34 N = 30 N = 36 N = 36
*Data are presented as median (range); sample size per measurement is indicated.
†P < 0.0001 comparing control to sarcoidosis.
¥P < 0.001 comparing control to sarcoidosis.
‡P < 0.0253 comparing control to sarcoidosis.
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markers of inflammation as well as “sarcoidosis-related”
serum markers, such as sIL2R, ESR, CRP, and ACE level,
did not correlate with pulmonary function measures or
severity score.
Correlations with disease progression
Twenty-six subjects with sarcoidosis had longitudinal data
(Table 3), meaning they had at least 2 serum samples. In
the longitudinal measurements, the majority of subjects
with chronic sarcoidosis demonstrated persistently ele-
vated or increased serum CXCL10 levels, whereas remit-
ting sarcoidosis subjects consistently showed a decrease in
serum CXCL10 (Figure 5). The mean increase in serum
CXCL10 in chronic sarcoidosis was 4.3 ± 14 pg/ml,
compared to a drop of 12.8 ± 11 pg/ml in the remitting
sarcoidosis group, p = 0.002 (Figure 5). Patients with
chronic sarcoidosis demonstrated a mean decline in
FVC of 0.13 L ± 0.13 L, whereas remitting subjects
demonstrated a mean improvement in FVC of 0.11 ±
0.34 L (p = 0.051). There was no difference in time interval
between performing pulmonary function testing betweenFigure 1 Comparison of serum CXCL9 (N = 30), CXCL10 (N = 36), and sIL
subjects. Data are presented as median and interquartile range. *p < 0.0001.both groups (10.3 ± 5.3 versus 8.9 ± 5.2 months, respect-
ively, p = 0.53).
To determine whether changes in immunosuppression
influenced change in CXCL10 levels in this longitudinal
analysis, we performed a sensitivity analyses. We defined
three groups of subjects based on immunosuppression
use: 1) remitting disease (not on immunosuppression at
any time), 2) chronic disease patients with no change in
immunosuppression (N =7) and 3) chronic disease pa-
tients in whom systemic immunosuppression was de-
creased in dose over time (N = 4). No subject had an
increase in immunosuppression and 2 subjects were ex-
cluded from the sensitivity analysis because the dosages
of immunosuppressive therapy were missing. We found
that CXCL10 levels decreased in remitters (−11.6 ±
11 pg/ml), showed little change in chronic disease when
immunosuppression was unchanged (−2.7 ± 12 pg/ml),
and increased in chronic disease when immunosuppres-
sion was decreased (+10.1 ± 15 pg/ml) (p = 0.015 for
trend test, Figure 6). These data suggest that CXCL10
levels may reflect disease activity, decreasing in remitting
patients, remaining elevated in those with chronic-2R (N = 36) protein levels in non-immunosuppressed sarcoidosis
Figure 2 Serum levels of CXCL10 and CXCL9 in non-
immunosuppressed subjects with sarcoidosis (N = 30).
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sion is decreased in the presence of chronic disease.
Subjects with chronic sarcoidosis were also likely to show
persistent elevations in CXCL9 compared to those with re-
mitting sarcoidosis; however, the difference in change of
CXCL9 over time between these groups did not reach
statistical significance (+7.22 pg/ml versus −5.19 pg/ml
in chronic and remitting groups, respectively; p = 0.37).
Changes in ACE, CRP, ESR, and sIL2R at follow-up did
not correlate with disease progression (data not shown).
Discussion
Based on our prior data showing upregulation of many
genes related to Type I and II interferon signaling path-
ways in the blood, as well as clinical studies measuringFigure 3 Relationship between interferon-inducible chemokines and
with FVC% predicted and (N = 36) (B) serum CXCL9 is inversely correlated
with sarcoidosis.elevated levels of IFN-γ-inducible chemokines in BALF
[10–13], we hypothesized that circulating blood levels of
the IFN-γ-inducible chemokines, CXCL9 and CXCL10,
would reflect disease severity and clinical course over
time. We found that CXCL9 and CXCL10 were indeed
elevated in the serum of sarcoidosis subjects compared
to controls and further, found that their levels correlated
with the lung function measurements DLCO and FVC,
respectively. In addition, we found that both chemokines
correlated with a clinical severity score, which takes into
account not only lung function measures, but also in-
volvement of organs such as cardiac and the nervous
system [22]. In the longitudinal analysis, subjects with
chronic sarcoidosis were significantly more likely to
show persistent elevations in CXCL10, whereas those
with remitting sarcoidosis had declines in CXCL10 over
time.
Although both CXCL9 and CXCL10 are IFN-γ-
inducible proteins, our results suggest that changes in
CXCL10 may play a larger role in, or track more closely
to, disease progression compared to CXCL9. Although
CXCL9 levels were correlated with CXCL10 levels and
the direction of change in CXCL9 trended with direction
of disease course, the difference in change of CXCL9 at
follow-up between the chronic and remitting groups did
not reach statistical significance. We speculate that the
difference between CXCL9 and CXCL10 serum levels
may, in part, be explained by the fact that CXCL10 pro-
duction is also strongly induced by Type I interferons
(α/β), which is not the case for CXCL9 [5,24]. Thus, in-
dividual sarcoidosis patients with higher circulating
levels of CXCL10 compared to CXCL9 may have greater
activation of the Type I and II interferon pathways,
which we speculate could identify subsets of sarcoidosis
phenotypes. In support of this idea, Antoniou et al.
found a 12-fold elevation of circulating CXCL10 but
non-significant elevation CXCL9 in sarcoidosis subjectspulmonary function testing. (A) Serum CXCL10 is inversely correlated
with DLCO% (N = 23) predicted in non-immunosuppressed subjects
Figure 4 Relationship between interferon-inducible chemokines and clinical severity. (A) Serum CXCL10 (N = 36) and (B) CXCL9 (N = 30)
positively correlated with a sarcoidosis severity score previously published by Wasfi et al.
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blood gene expression data from sarcoidosis and control
subjects confirmed that transcripts for CXCL10 were
significantly more upregulated compared to CXCL9 in
sarcoidosis (Gene Expression Omnibus, GSE19314).
Notably CXCL10 is strongly expressed in sarcoidosis
tissues [10]. Furthermore, a number of studies have mea-
sured CXCL10 in BALF from sarcoidosis patients [10–
13,26]. CXCL10 has been shown to play a significant
role in granulomatous inflammation. In mice models of
granulomatous disease induced by Propionobacterium
acnes, CXCL10 has been shown to be necessary for the
formation of Th1 lymphocyte clusters in draining lymph
nodes [27], and blockade of CXCR3 (the receptor for
CXCL9 and CXCL10) and CCR5, inhibits the formation
of granulomas in lungs [28]. In models of hypersensitivityTable 3 Clinical characteristics of longitudinal cohort by disea





Time from diagnosis to baseline blood draw (years)*
Scadding stage at enrollment (I/II/III/IV)




Number of subjects receiving immunosuppression at time of baseline
blood draw or follow-up blood draw
Δ in serum CXCL10 (pg/ml)*
Interval between baseline and follow-up visits (months)*
Δ in FVC (L)*
*Data expressed as mean ± SD.
**Systemic immunosuppression history includes medications that were ever taken fpneumonitis, CXCL10 has also been shown to be neces-
sary for granuloma formation [29,30]. Induction of
CXCR3 with CXCL9 and/or CXCL10 allows for T cell mi-
gration into organ tissues, including those that are typic-
ally thought of as immune privileged, and contributes to
Th1 cell differentiation, which are common features of
sarcoidosis [31,32]. Interestingly, serial measurements of
serum CXCL10 has been correlated with persistence or
resolution of autoimmune thyroid disease [33], which is
seen frequently with sarcoidosis [34]. Taken together,
these findings could suggest that CXCL10 may contribute
to Th1 cell recruitment and promote granulomatous in-
flammation in chronic sarcoidosis.
We also found that CXCL10 remained elevated among
chronic sarcoidosis subjects compared to healthy con-
trols despite immunosuppression use. Since use ofse progression
Chronic Remitting
13 13
9 (69%) 8 (62%)
53.3 ± 12 54.3 ± 11.5
10/3/0 12/0/1




ethotrexate + prednisone +
uenil, 1 prednisone + plaquenil
1 prednisone, 1 methotrexate +
prednisone, 11 never treated
8 0
+4.3 ± 14 -11.6 ± 11
6.47 ± 1.55 6.90 ± 1.89
-0.13 ± 0.13 +0.11 ± 0.34
or sarcoidosis, and not necessarily medications taken at time of blood draws.
Figure 6 The effect of systemic immunosuppression (IS) on
serum CXCL10. In remitting disease subjects who did not receive IS
at baseline and followup (N = 13), CXCL10 declined spontaneously.
In chronic disease, CXCL10 remained largely unchanged if
immunosuppression was unchanged (N = 7), and increased if
immunosuppression was decreased (N = 4). *denotes a statistically
significant result using the non-parametric trend test.
Figure 5 Changes in serum CXCL10 levels correspond to sarcoidosis disease course. CXCL10 remains persistently elevated in patients with
chronic sarcoidosis (N = 13). CXCL10 declines over time in patients with remitting sarcoidosis (N = 13). Longitudinal serum CXCL10 levels in 14
healthy controls are presented for comparison.
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potentially affect CXCL10 levels, we performed a sensi-
tivity analysis, classifying patients with chronic disease
according to changes in immunosuppression levels over
time. This analysis revealed that CXCL10 levels remain
elevated in patients classified as having chronic disease
when immunosuppression is unchanged, but that
CXCL10 levels increased further when immunosuppres-
sion was reduced.
With regard to serum sIL2R levels, we found signifi-
cant elevations in patients with sarcoidosis which is con-
sistent with prior data [35–38]; however, sIL2R levels
failed to correlate with measures of disease activity or
disease progression. This negative finding is compatible
with the results of Grutters and colleagues, who showed
that there were no differences in sIL2R between sarcoid-
osis subjects with or pulmonary function abnormalities
[39]. Three other studies did not find any correlations in
serum sIL2R with BAL fluid analyses [37,38,40]. Ziegen-
hagen et al. reported that an elevated serum sIL2R mea-
sured once at baseline was associated with progressive
disease [36], which our and Grutters’ results do not sup-
port [39]. In contrast to our study, in the Ziegenhagen
et al. cohort, the distinction between progressive and
stable disease was made based on the patient’s disease
course over a 6-month window after initial diagnosis,
and these studies did not have follow-up measurements
of sIL2R. Also, interpretation of sIL2R levels may be
confounded by varying degrees of peripheral lymphope-
nia often observed in sarcoidosis independent of im-
munosuppression [1,41], since sIL2R is, in part, released
by activated T lymphocytes [42]. Finally, sIL2R may be
potentially affected by corticosteroid treatment in sar-
coidosis [38,40]. Taken together, the characteristics ofsIL2R may be the reason that it has not proven to reli-
ably track with disease course.
There are important limitations to our study. Our co-
hort represented a single institution experience and al-
though UCSF serves a multi-ethnic urban area, this
study included predominantly white patients. Our sam-
ple size is limited and our findings warrant further study
in larger validation cohorts. Although categorization of
Su et al. Respiratory Research 2013, 14:121 Page 8 of 9
http://respiratory-research.com/content/14/1/121sarcoidosis subjects for clinical studies could be viewed
as somewhat arbitrary, the goal in this study was to use
a stratification system that had prior acceptance given
the limitations of any categorization schema. The clinical
classification scheme that we used to categorize sarcoid-
osis subjects as chronic vs. remitting was based upon
previously published studies [18–21]. These studies de-
fined chronic disease as sarcoidosis subjects who re-
quired systemic immunosuppression for recurrent or
ongoing disease activity 2 years after their initial diagno-
sis. Remitting sarcoidosis subjects included patients who
did not require systemic immunosuppression beyond
2 years after diagnosis, or never required immunosup-
pression. We could not apply the clinical categorizations
of acute and non-acute sarcoidosis disease onset re-
ported by Prasse et al. [43] since our cohort consisted of
only non-acute disease.
Conclusions
In summary, we found that serum CXCL9 and CXCL10
levels correlated with sarcoidosis disease severity as assessed
by FVC and DLCO, as well as the Wasfi severity score,
which incorporates additional clinical phenotypes of
sarcoidosis. Changes in serum CXCL10 levels over time
correlated with both chronic progressive disease (asso-
ciated with sustained elevations of CXCL10) or remit-
ting sarcoidosis (associated with a reduction over time
in CXCL10). Our findings in the peripheral blood,
along with data from several other cross-sectional
BALF studies, suggest that CXCL9 and CXCL10 may
play important roles in the pathogenesis of sarcoidosis.
Larger replicate studies are needed to validate our
findings.
Additional files
Additional file 1: Patient selection flow diagram for cross-sectional
versus longitudinal cohorts. This diagram depicts the selection criterion
for sarcoidosis subjects in the cross-sectional and longitudinal analyses
and, within the longitudinal cohort, the definitions of chronic versus
remitting sarcoidosis.
Additional file 2: Characteristics of Cross-Sectional Sarcoidosis
Subjects with Normal versus Low Pulmonary Function Testing. This
table compares the characteristics of cross-sectional sarcoidosis subjects
with low pulmonary function testing (as defined by a FVC or DLCO of
less than 80 percent predicted) with sarcoidosis subjects with normal
pulmonary function testing.
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